Aileron Therapeutics to Present at Two Upcoming May 2024 Investor Conferences

2024-05-06

临床2期快速通道孤儿药临床1期

AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences: Citizens JMP Life Sciences Conference Date: Monday, May 13, 2024 Time: 12:00 p.m. EDT Format: Company presentation H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ Date: Monday, May 20, 2024 Time: 5:00 p.m. EDT Format: Fireside chat A live webcast of the events can be accessed at . Replays of the webcasts will be available for 90 days following the presentations. About Aileron Therapeutics Aileron Therapeutics is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Aileron’s lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Currently, LTI-03 is being evaluated in a Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis, with Cohort 2 results expected to be reported in the third quarter this year. Aileron’s second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the US and EU and Fast Track Designation in the US. Investor Relations & Media Contact: Argot Partners aileron@argotpartners.com 212-600-1902

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构